VNX-206

VNX-206 is an investigational AAV-delivered T-cell immuno-gene therapy being developed by Vironexis Biotherapeutics for the treatment of osteosarcoma. Built on the proprietary TransJoin™ platform, the therapy utilizes an adeno-associated virus (AAV) vector delivered via a single intramuscular injection. Once administered, the vector programs the patient's muscle cells to produce and secrete bispecific T-cell engagers into the bloodstream. These engineered proteins are designed to bridge the patient's endogenous T cells with osteosarcoma cells by binding simultaneously to the CD3 receptor on T cells and a specific tumor-associated antigen on the cancer cells. This approach aims to trigger a potent T-cell mediated anti-tumor response while avoiding the complexities and toxicities associated with traditional ex vivo CAR-T cell therapies or frequent bispecific antibody infusions.